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Abbreviations 
 
2-DG – 2-[14C(U)]-deoxy-D-glucose; Akt – protein kinase B; p-Akt – phosphorylated Akt; 
AMPK – 5′ adenosine monophosphate-activated protein kinase; BCA – bicinchoninic acid; 
CS – catechol-O-sulfate; DCF – 2′,7′-dichlorofluorescin; DCFH-DA – 2′,7′-
dichlorofluorescin diacetate; DHFA – dihydroferulic acid; DHFA-4S – dihydroferulic acid 4-
sulfate; FA4S – ferulic acid 4-O-sulfate; GLUT – glucose transporter; Glc/Ins –
glucose/insulin; GYS1 – glycogen synthase; INSR – insulin receptor; IRS – insulin receptor 
substrate; IVA – isovanillic acid; IVAS – isovanillic acid 3-O-sulfate; K3G – kaempferol 3-
O-β-D-glucuronide; MCS – 4-methylcatechol-O-sulfate; MGS – 4-methylgallic-3-O-sulfate; 
OAT – organic anion transporter; PCA – protocatechuic acid; PI3K – phosphatidylinositol-
4,5-bisphosphate 3-kinase; PGS – pyrogallol-O-sulfate; PKC – protein kinase C; Q3G – 
quercetin 3-O-β-D-glucuronide; Q3S – quercetin 3′-O-sulfate; R3G – trans-resveratrol 3-O-
glucuronide; R4G – trans-resveratrol 4′-O-β-D-glucuronide; R3S – trans-resveratrol 3-
sulfate; SLC22A(6, 7, 8, 11) – solute carrier family 22 member (6, 7, 8, 11); VAS – vanillic 
acid-4-O-sulfate.  
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Abstract 
 
The gut microbiome supplies essential metabolites such as short chain fatty acids to skeletal 
muscle mitochondria, and the composition and activity of the microbiota is in turn affected 
by muscle fitness. To further our understanding of the complex interactions between the gut 
microbiome and muscle, we examined the effect of microbiota-derived phenolic metabolites 
on the ability of human muscle cells to take up and metabolize glucose. As a model, we used 
the differentiated human skeletal muscle myoblast line, LHCN-M2, which expresses typical 
muscle phenotypic markers. We initially tested a selected panel of parent phenolic 
compounds and microbial metabolites, and their respective phenolic conjugates, as found in 
blood. Several of the tested compounds increased glucose uptake and metabolism, notably in 
high glucose and insulin-treated myotubes. One of the most effective was isovanillic acid 3-
O-sulfate (IVAS), a metabolite from the microbiome found in the blood, primarily derived 
from consumed cyanidin 3-O-glucoside, a major compound in berry fruits. IVAS stimulated a 
dose-dependent increase in glucose transport through a GLUT4- and PI3K-dependent 
mechanism. IVAS also upregulated GLUT1, GLUT4 and PI3K p85α protein, and increased 
phosphorylation of Akt. The stimulation of glucose uptake and metabolism by a unique 
microbiome metabolite provides a novel link between the diet, gut microbiota and skeletal 
muscle energy source utilization.  
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Introduction 
 
Skeletal muscle is the primary site of postprandial glucose disposal (1), where the glucose 
transporter GLUT4 is activated in response to insulin by translocation from internal vesicles 
to the plasma membrane (2, 3). In diabetic and pre-diabetic insulin-resistant tissues, insulin 
driven GLUT4 translocation is compromised (4). Therapeutic strategies against insulin 
resistance, including exercise and diet-related interventions, aim at lower postprandial 
glycemia at least partly by restoring skeletal muscle glucose uptake and enhancing 
metabolism (5, 6). One of the most commonly studied classes of gut microbial metabolites 
are short chain fatty acids (SCFA), which affect host metabolism by acting on mitochondria 
in skeletal muscle cells, and indeed an important SCFA, butyrate, is correlated with fitness 
levels (7). Further, the gut microbiome has a profound influence on inflammatory states (8) 
and on metabolism during exercise (9); as such trained athletes have a distinctly different 
microbiome compared to sedentary individuals (10). Endurance exercise requires enhanced 
energy-generating processes, with increased mitochondrial biogenesis leading to elevated 
ROS. The gut microbiota regulate mitochondrial biogenesis through modulation of PGC-1α, 
SIRT1 and AMPK as suggested, for example, by studies where germ-free mice had elevated 
AMPK and PGC-1α expression in skeletal muscle (11). The gut microbiota-produced 
metabolites such as SCFA and secondary bile acids can also contribute to host energy 
production. In return, mitochondria regulate some aspects of the gut microbiota by 
modulating intestinal barrier function and mucosal immune responses (12). 
 
One of the ways in which the microbiome communicates with the body is through production 
of distinctive biologically active metabolites. Some of these, such as butyrate, have been well 
studied (13), and multiple actions have been observed in muscle and other tissue (7, 14). 
Butyrate is mainly derived from “prebiotic” dietary fiber which is undigested in the small 
intestine, enters the colon and acts as a fermentation substrate for the microbiota (15, 16). 
Dietary phenolics are another class of common prebiotic-type molecules, and this group 
includes precursor molecules found in unbound form as well as those covalently attached to 
some dietary fibers such as cereal brans (17). After microbial action, many potentially 
bioactive compounds are released and absorbed in the colon from multiple substrates, 
including phenolics (18, 19), but the action of these compounds on the body is only 
beginning to be explored (20, 21). The situation is complicated by the range of possible 
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modifications that can occur in vivo such as glucuronidation, sulfation, glutathionylation and 
methylation (22, 23); however, these modified compounds can be present in the blood at high 
concentrations and remain for long periods of time, increasing the exposure time to body 
tissues and organs (19).  
 
Since rodent muscle cells show substantial differences to human cells, including (a) the 
myogenic programming that regulates differentiation (24) and (b) glucose transport kinetics 
in response to insulin and GLUT4 expression (25), in the work presented here we specifically 
chose to use differentiated human muscle cells to understand the mechanisms linking the gut 
microbiome to glucose uptake. In addition, as immortalized human muscle cell lines rarely 
retain their muscle phenotype, as part of this work we further characterized and exploited the 
LHCN-M2 immortalized human skeletal muscle cell line (26). We then exposed these cells to 
metabolites of microbial catabolism of commonly-consumed phenolics and examined their 
effect on glucose uptake and metabolism, especially relevant to post-prandial physiology, 
insulin responses and type 2 diabetes.  
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Materials and Methods 
 
Chemical compounds and reagents 
 
All reagents were purchased from Sigma-Aldrich (Gillingham, UK) unless otherwise stated. 
High purity (18.2 MΩ cm-1) water supplied by a MilliQ system (Merck Millipore UK, 
Watford, UK) was used throughout. Ferulic acid 4-O-sulfate (FA4S) and dihydroferulic acid 
4-O-sulfate (DHFA-4S) were synthesized according to (27). Dihydroferulic acid (DHFA) 
was purchased from Alfa Aesar (Thermo Fisher Scientific, Warrington, UK). Quercetin 3′-O-
sulfate (Q3S) was synthesized as previously described (28). Quercetin 3-O-β-D-glucuronide 
(Q3G), kaempferol 3-O-β-D-glucuronide (K3G) and isovanillic acid (IVA) were from Sigma-
Aldrich. Trans-resveratrol 4′-O-β-D-glucuronide (R4G), trans-resveratrol 3-O-sulfate (R3S) 
and trans-resveratrol 3-O-β-D-glucuronide (R3G) were from Bertin Pharma (Montigny-le-
Bretonneux, France). Catechol-O-sulfate (CS), 4-methylcatechol-O-sulfate (MCS), 
pyrogallol-O-sulfate (PGS), 4-methylgallic acid 3-O-sulfate (MGS), vanillic acid 4-O-sulfate 
(VAS) and isovanillic acid 3-O-sulfate (IVAS) were chemically/enzymically synthesized and 
characterized as described previously (29, 30). 2-[1-14C(U)]-deoxy-D-glucose and D-
[14C(U)]-glucose were both from PerkinElmer (Beaconsfield, UK). 
 
Cell culture and differentiation of LHCN-M2 myoblasts  
 
LHCN-M2 myoblasts are derived from a selected myogenic clone of an immortalized 
population of human satellite cells, originally from the pectoralis major muscle of a 41-year 
old Caucasian heart-transplant donor (26). Myoblasts were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco, Life Technologies, Thermo Fisher Scientific, UK) 
supplemented with 5.5 mM glucose, 10% v/v heat-inactivated fetal bovine serum, 10% v/v 
heat-inactivated newborn calf serum (Gibco), animal-free recombinant human epidermal 
growth factor (5 µg; PeproTech, London, UK), animal-origin free recombinant human basic 
fibroblast growth factor (0.5 µg; Gibco) and dexamethasone (200 µg), and sterile-filtered. 
Cells were passaged before reaching confluence, at least every 4 d. For experiments, once 
myoblasts reached ~80-90% confluence they were differentiated to myotubes for 96 h 
following replacement of growth medium with differentiation medium (DMEM 
supplemented with 5.5 or 25 mM glucose, 10 or 50 nM recombinant human insulin (Sigma-
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Aldrich) and 2% horse serum (Gibco)). Differentiation medium was changed every day. The 
progress of differentiation was monitored daily by observing the formation of elongated and 
multinucleated myotubes using an inverted microscope (Leica MD IL LED) and 
characterization of myotube formation is shown in the Results section (Fig. 1). Cells were 
kept in a humidified atmosphere of 5% CO2/95% air at 37oC and used for experiments over 
six passages. Sub-culturing was done in 75 or 175 cm2 flasks and for experiments, cells were 
seeded on 6-well plates (Corning, Appleton Woods, UK), 100 or 150 mm dishes (Greiner 
CELLSTAR, Stonehouse, UK) at a density equivalent to ~1.8 x 104 cells cm-2.  
 
Measurement of LHCN-M2 myoblast viability  
 
Viability of LHCN-M2 myoblasts was assessed using the Trypan Blue exclusion assay (31). 
Cells were lifted with 0.05% trypsin-EDTA, resuspended in growth medium, an aliquot was 
mixed 1:1 (v/v) with 0.4% Trypan Blue-PBS and the cells were counted on the 
hemocytometer. 
 
Treatment of LHCN-M2 myotubes for protein analysis 
 
Stocks of compounds (Fig. 2) were dissolved in DMSO (at a final maximum 0.2% v/v 
concentration) and diluted in cell culture medium. LHCN-M2 myotubes, differentiated for 96 
h in 5.5 mM glucose and 10 nM insulin, or in 25 mM glucose and 50 nM insulin as described 
above, were starved of glucose, insulin and serum in the presence of test compound(s) or 
appropriate DMSO control for 4 h before experiments. After washing twice with PBS, 
LHCN-M2 myotubes were scraped into PBS supplemented with 1% (v/v) protease and 
phosphatase inhibitors cocktail (Roche, Sigma-Aldrich, UK) and centrifuged at 500 g, 4oC 
for 5 min. PBS was aspirated and the pellet was snap-frozen in a dry ice/ethanol bath. 
Samples were stored at -80oC until analysis. Cell pellets were lysed in Bicine/CHAPS lysis 
buffer (ProteinSimple, Bio-Techne, San Jose, CA, USA) and the total protein was measured 
by the bicinchoninic acid (BCA) method (32). Whole cell lysates of HepG2, Caco-2/TC7 and 
HUVEC cells prepared in the same way were used as negative controls for the GLUT4 
analysis and human skeletal muscle whole tissue lysate (Novus, Bio-Techne) diluted in 
Bicine/CHAPS served as a positive control. 
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Protein analysis by automated Western blotting in nanocapillaries (ProteinSimple) 
 
Whole cell lysates were analyzed for protein by automated western blotting, “WES” 
(ProteinSimple, Bio-Techne) according to the manufacturer’s guidelines. Samples were 
denatured at 37oC for 20 min in Bicine/CHAPS. Troponin T (mouse anti-troponin T 
(cardiac), CT3, Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, 
USA) was used as a marker of differentiated muscle (33), PI3K subunit p85α as a marker of 
the insulin signaling pathway proteins (34) (mouse anti-PI3K (subunit p85α), MAB2998, 
Novus, Bio-Techne), and rabbit anti-Akt (#9272, Cell Signaling Technology, Beverley, MA, 
USA) and rabbit anti-phospho-Akt (Ser473) (Cell Signaling Technology) were used to 
determine the p-Akt/Akt ratio, a marker of insulin signaling pathway activation (35). Mouse 
anti-GLUT4 (1F8) was also from Cell Signaling Technology and rabbit anti-GLUT1 
(ab115730) was from Abcam (Cambridge, UK). Antibodies were duplexed with mouse anti-
α-actinin 1 (MAB8279, Novus, Bio-Techne) or rabbit anti- -α-actinin ((D6F6) XP #6487, 
Cell Signaling Technology) as loading controls. Mouse or rabbit secondary antibodies were 
used neat as supplied (ProteinSimple). Samples were loaded onto the “WES” system at a 
final total protein concentration of 0.4 mg/ml for troponin T/α-actinin 1 and for PI3K p85α/α-
actinin 1, 0.5 mg/ml for GLUT4/α-actinin 1 and 0.1 mg/ml for GLUT1/α-actinin and for (p-
)Akt/α-actinin. See supplementary figures (S1-S5) for full setup and validation of antibodies.  
 
Uptake of 2-[1-14C(U)]-deoxy-D-glucose and D-[14C(U)]-glucose  
 
Following the 4 h incubation with test compounds or control, LHCN-M2 myotubes were 
further incubated with various insulin concentrations, test compounds or DMSO in 0.55 mM 
deoxy-D-glucose (0.15 µCi/ml 2-[1-14C(U)]-deoxy-D-glucose) in DMEM for 30 min, or in 
0.55 mM glucose (0.2 µCi/ml D-[14C(U)]-glucose) in DMEM for 4 h. Cells were then washed 
twice with medium (without glucose and serum) and lysed in 1M NaOH for radioactivity 
measurements by liquid scintillation counting on a Tri-Carb 1900 TR Liquid Scintillation 
Analyzer (Canberra Packard, Harwell, Oxford, UK). Counts were corrected for total protein, 
measured with the Bradford assay (Thermo Fisher Scientific) (36, 37).  
 
2´,7´-dichlorofluorescin diacetate (DCFH-DA) assay 
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The DCFH-DA assay was conducted as described previously (38). Briefly, cells were washed 
with PBS, incubated with 10 µM DCFH-DA in PBS at 37oC for 20 min in darkness, washed 
again and fluorescence measured on a PheraSTAR FS (BMG LabTech) plate reader (Ex/Em 
= 485/530 nm). Cells were then scraped and lysed into CellLytic supplemented with 1% (v/v) 
protease inhibitor cocktail and total protein was measured using the Bradford assay. 
Fluorescence was corrected for protein. 
 
Statistical analyses 
 
Data are expressed as mean ± standard error of the mean. The significance of differences 
between groups of treatments was analyzed by one-way ANOVA and post hoc Tukey’s (for 
unequal sample sizes), Dunnett’s (comparing multiple treatments to a single control) or two-
tailed t-tests accordingly, with variance checks using Levene’s test, and with Bonferroni 
correction where multiple treatments were compared, using SPSS 24. A p value < 0.05 was 
considered as statistically significant.  
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Results 
 
Characterization of differentiated human skeletal muscle LHCN-M2 myotubes 
 
LHCN-M2 myoblasts gradually differentiated into myotubes, as identified by multinucleated 
fibers formed by fused cells (Fig. 1A). During the differentiation process α-actinin 1 levels 
were stable while troponin T increased by ~ 50% every 24 h (Fig. 1B). Insulin dose-
dependently increased 2-[1-14C(U)]-deoxy-D-glucose (Fig. 1C) and D-[14C(U)]-glucose 
uptake (Fig. 1D). In contrast, in undifferentiated myoblasts, insulin did not stimulate 2-[1-
14C(U)]-deoxy-D-glucose uptake (Fig. 1E). Differentiation in high glucose, compared to 
normal glucose, increased DCF fluorescence as a marker of reactive oxygen species (ROS), 
which was further amplified by insulin (Fig. 1F). Troponin T and GLUT4 protein levels 
increased with differentiation but were unaffected by glucose and insulin concentration used 
(Fig. 1G and H). In comparison, GLUT1 protein expression was decreased by approximately 
25% by the end of the differentiation period in the cells in 5.5 mM glucose and 10 nM 
insulin, and by a further 10% in the cells in higher glucose and insulin (Fig. 1I). Subsequent 
experiments were performed on cells differentiated for 96 h in either 5.5 mM glucose with 10 
nM insulin, or in 25 mM glucose with 50 nM insulin, referred to hereafter as “normal” or 
“high” glucose/insulin (Glc/Ins) respectively. In the absence of insulin, 5.5 and 25 mM 
glucose are referred to as “normal” and “high” glucose respectively.  
 
Effect of metabolite mixtures on 2-[1-14C(U)]-deoxy-D-glucose uptake in differentiated 
human skeletal muscle LHCN-M2 myotubes 
 
Insulin stimulated the uptake of 2-[1-14C(U)]-deoxy-D-glucose, a non-metabolizable form of 
glucose used as a measure of intracellular glucose transport only (39), in LHCN-M2 
myotubes (Fig. 3). In cells differentiated in normal Glc/Ins, and in the absence of insulin in 
the assay, a combination of ferulic acid derivatives (FA4S, DHFA-4S and DHFA, Fig. 2A) or 
of flavonol conjugates (Q3S, Q3G and K3G, Fig. 2B) exhibited no effect (Fig. 3A and B), 
whereas the resveratrol conjugates combination (R4G, R3S and R3G, Fig. 2C) and the 
phenolic conjugates mixture (CS, MCS, PS, MGS, VAS and IVAS, Fig. 2D) significantly 
stimulated 2-[1-14C(U)]-deoxy-D-glucose uptake similar to insulin (Fig. 3C and D). In the 
presence of insulin the effective combinations did not produce further changes, while the 
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ferulic acid derivatives even led to attenuation of insulin activity (Fig. 3A-D). For the cells 
differentiated in high Glc/Ins, and without insulin in the assay, all of the treatments except for 
the flavonol conjugates stimulated (deoxy)glucose uptake, displaying an insulin-like effect. 
Notably, the effect of insulin was enhanced in the presence of the phenolic conjugates (Fig 
3D). Based on these data, the phenolic conjugates exerted a robust insulin-like effect on 
(deoxy)glucose transport into LHCN-M2 myotubes differentiated both in the presence of 
normal and high glucose/insulin. 
 
Effect of metabolite mixtures on D-[14C(U)]-glucose uptake in differentiated human 
skeletal muscle LHCN-M2 myotubes 
 
The assays using D-[14C(U)]-glucose indicate the rate of glucose uptake and subsequent 
metabolism over the longer time period (4 h). Performing these assays alongside the acute 
assays with 2-[1-14C(U)]-deoxy-D-glucose elucidates whether the subsequent metabolism is 
likely anabolic or catabolic. For example, an effect whereby acute uptake with 2-[1-14C(U)]-
deoxy-D-glucose was increased, but intracellular D-[14C(U)]-glucose after 4 h was decreased, 
would indicate that glucose transport, catabolism and expulsion from the cells was increased. 
However, increased transport and increased intracellular 14C-label after 4 h would indicate 
anabolism, with glucose being converted to glycogen for example (4). In cells differentiated 
under normal Glc/Ins concentrations, none of the metabolite mixtures affected D-[14C(U)]-
glucose uptake and metabolism significantly, except for the resveratrol conjugates which 
slightly suppressed it (Fig. 3E to H). Insulin-stimulated uptake of D-[14C(U)]-glucose in 
LHCN-M2 myotubes was not changed by any of the tested combinations in normal Glc/Ins 
cells (Fig. 3).However, for the high Glc/Ins-differentiated cells, where intracellular ROS 
levels are higher according to the DCF assay, the results were somewhat different. In the 
absence of insulin (in the assay), ferulic acid derivatives and resveratrol conjugates decreased 
D-[14C(U)]-glucose uptake, indicating an opposing effect to insulin and increased catabolism, 
while the flavonol and phenolic conjugates had no obvious effect (Fig. 3E and G). In the 
presence of insulin, the flavonol conjugates and the resveratrol conjugates attenuated D-
[14C(U)]-glucose uptake, indicating a blunting of the insulin effect, while ferulic acid 
derivatives and phenolic conjugates did not influence insulin activity. 
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Effect of individual metabolites on 2-[1-14C(U)]-deoxy-D-glucose and D-[14C(U)]-glucose 
uptake in differentiated human skeletal muscle LHCN-M2 myotubes 
 
As the most notable effects of the metabolite mixtures were observed under high glucose, and 
consequently highest metabolic and oxidative stress, we tested individual metabolites 
predominantly under these conditions. Across all compounds, increases in 2-[1-14C(U)]-
deoxy-D-glucose uptake were primarily due to sulfated conjugates: FA4S and DHFA-4S 
increased uptake by ~15% (p < 0.05) (Fig. 4A), R3S by ~25% (p < 0.001) (Fig. 4C) and 
IVAS by ~40% in addition to the insulin-stimulated increase (p < 0.001) (Fig. 4D). The only 
glucuronide conjugate to exert an effect was R4G, with a ~25% increase (p < 0.01) (Fig. 4C). 
Individual flavonol conjugates were inactive (Fig. 4B). For uptake of D-[14C(U)]-glucose into 
LCCN-M2 myotubes, DHFA-4S and R4G decreased intracellular 14C-label, both 
independently of insulin (Fig. 4E, 4G). Q3G and K3G also lowered intracellular 14C-label in 
some conditions (Fig. 4F). Since IVAS was the most active of the phenolic conjugates on 2-
[1-14C(U)]-deoxy-D-glucose uptake (Fig. 4D), this metabolite was further examined. IVAS 
lowered intracellular 14C-label derived from D-[14C(U)]-glucose in the absence of insulin in 
myotubes differentiated in both normal and high Glc/Ins, however this was not evident in the 
presence of insulin (Fig. 4H). 
 
Mechanism of action of IVAS on LHCN-M2 myotubes 
 
IVAS dose-dependently increased 2-[1-14C(U)]-deoxy-D-glucose uptake (Fig. 5A, 5B), 
comparable to the action of insulin (Fig. 1C, 1D). Quantitatively, 2-[1-14C(U)]-deoxy-D-
glucose uptake was higher in myotubes differentiated in normal Glc/Ins, but the high Glc/Ins 
conditions made the cells more responsive to IVAS when considered as a fold change (Fig. 
5B). IVAS-stimulated uptake of 2-[1-14C(U)]-deoxy-D-glucose was observed both in the 
presence and absence of acute insulin, and also in myotubes differentiated under normal or 
high Glc/Ins (Fig. 5C). At a high concentration of IVAS (> 10 µM), where its effect reached 
a plateau, isovanillic acid (IVA) was equally effective (Fig. 5C) and thus the effects on 
LHCN-M2 not dependent on the sulfate group of the metabolite.  
 
The PI3K inhibitor wortmannin, and the GLUT4 inhibitor indinavir, both prevented insulin-
stimulated 2-[1-14C(U)]-deoxy-D-glucose uptake, but neither had an effect on basal uptake, 
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as expected. The effect of IVAS was also abolished by the same inhibitors (Fig. 5D). When 
treated with IVAS for only 30 min, i.e. bypassing the 4 h pre-treatment, 2-[1-14C(U)]-deoxy-
D-glucose uptake was still increased in LHCN-M2, although less pronounced than with the 
longer-term treatment, and the inhibitors also prevented the effect of this shorter term 
incubation (Fig. 5E). 
 
Expression of Troponin T protein, a differentiation marker, was unaffected by treatment with 
IVAS in both normal and high Glc/Ins (Fig. 6A) while GLUT4 expression was substantially 
increased in both normal and high Glc/Ins by ~60% (p < 0.001) (Fig. 6B). IVAS treatment 
restored protein levels of GLUT1, suppressed by 20% under high Glc/Ins conditions, but did 
not further increase GLUT1 protein expression (Fig. 6C). PI3K p85α protein was increased 
by IVAS in both normal and high Glc/Ins conditions, with a more pronounced effect in the 
latter (Fig. 6D). Akt phosphorylation was increased by insulin and inhibited by wortmannin 
as expected, and was increased by IVAS in both normal and high Glc/Ins conditions (Fig. 
6E). The combination of IVAS and insulin appears to be synergistic for increasing Akt 
phosphorylation (Fig. 6E).  
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Figure 1: LHCN-M2 myoblasts differentiate to insulin-responsive myotubes.  
Myoblasts were grown to confluence, and then in 5.5 mM glucose and 2% serum only for 96 
h. Images were taken daily using an inverted microscope at 10X magnification (A). Troponin 
T and α-actinin 1 proteins were quantified by automated capillary Western blotting (for setup 
see Fig. S1) using total cell lysates sampled during the differentiation procedure. Mean ± 
SEM (N = 3) (B). Differentiated myotubes were starved of glucose and serum for 4 h and 
then incubated with various insulin concentrations and 2-[14C(U)]-deoxy-D-glucose (2-DG; 
0.55 mM; 0.15 µCi/ml) for 30 min (C) or D-[14C(U)]-glucose (0.55 mM; 0.2 µCi/ml) for 4 h 
(D). Data are corrected against a standard curve for 14C-label and presented as µg sugar/mg 
total protein. Uptake of 2-[1-14C(U)]-deoxy-D-glucose or D-[14C(U)]-glucose with and 
without 25 or 100 nM insulin respectively was measured in myotubes and myoblasts (E). All 
uptake data are mean ± SEM (N/n = 4/12 (C); 5/24 (D); 4/12 (E)). After differentiation for 96 
h in 5.5 mM glucose or 25 mM glucose with various concentrations of insulin, 2´,7´-
dichlorofluorescin (DCF) fluorescence was measured after incubation with 10 µM 2´,7´-
dichlorofluorescin diacetate (DCFH-DA) in PBS for 20 min. Mean ± SEM (N/n = 3/18) (F). 
Troponin T (G), GLUT4 (H) and GLUT1 (I) protein, all relative to α-actinin 1, were 
measured in total cell lysates of myotubes differentiated in 5.5 mM glucose (Glc) and 10 nM 
insulin (Ins) or 25 mM glucose and 50 nM insulin. Linearity of responses and assay setups 
are shown in Fig. S1-3. Data are mean ± SEM (N = 3). Different letters denote p < 0.05, *p < 
0.05, **p < 0.01, ***p < 0.001 for differences between treatments or time-points accordingly 
and p-values on figures are for differences between all points in each group.  
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Figure 2: Phenolic metabolites investigated for potential roles in modulating glucose 
uptake and metabolism in human skeletal muscle. 
Derivatives of ferulic acid (A); flavonol conjugates (B); resveratrol conjugates (C); phenolic 
sulfates in circulation after the consumption of berries (D). Boxed compounds originate 
predominantly from colonic microbiota metabolism, unboxed in the small intestine. 
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Figure 3: Effect of metabolite mixtures on 2-[1-14C(U)]-deoxy-D-glucose and D-[14C(U)]-
glucose uptake and metabolism in LHCN-M2 myotubes. 
Myotubes, differentiated for 96 h in 5.5 mM glucose and 10 nM insulin (normal) or in 25 
mM glucose and 50 nM insulin (high Glc/Ins), were starved of glucose, insulin and serum, in 
the presence of indicated compounds or DMSO, for 4 h. Myotubes were then incubated with 
a DMSO control, 100 nM insulin (Ins), the same compounds, or the same compounds plus 
100 nM insulin, with 0.15 µCi/ml 2-[14C(U)]-deoxy-D-glucose (2-DG; 0.55 mM) for 30 min 
(A-D); or with the same protocol but with 25 nM insulin and 0.2 µCi/ml D-[14C(U)]glucose 
(Glc; 0.55 mM) for 4 h (E-H). Data were normalized to the DMSO-containing normal Glc/Ins 
controls and shown as mean ± SEM (N/n = 4/12). Ferulic acid (FA) derivatives – FA4S, 
DHFA-4S and DHFA, all at 2 µM (A); flavonol conjugates – Q3S, Q3G and K3G, all at 2 
µM (B); resveratrol (Res) conjugates – R4G, R3S and R3G, all at 2 µM (C); phenolic sulfates 
(Phenolic Sulf) – CS, MCS, PS, MGS, VAS and IVAS, all at 5 µM (D). Different letters 
above bars indicate p < 0.05 between groups. 
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Figure 4: Effect of individual compounds on 2-deoxy-D-glucose uptake and glucose 
metabolism.  
Myotubes, differentiated for 96 h in 25 mM glucose and 50 nM insulin (High Glc/Ins), were 
starved of glucose, insulin and serum in the presence of a metabolite or DMSO control (Ctrl) 
for 4 h, and then incubated with the same compound ± 100 nM insulin and 0.15 µCi/ml 2-
[14C(U)]-deoxy-D-glucose (0.55 mM; 2-DG) for 30 min (A-D). Myotubes, differentiated for 
96 h in 5.5 mM glucose and 10 nM insulin (normal) or in high Glc/Ins, were starved of 
glucose, insulin and serum in the presence of a metabolite or DMSO control (labelled D) for 
4 h, then incubated with the same compound ± 25 nM insulin (Ins) and 0.2 µCi/ml D-
[14C(U)]glucose (0.55 mM; Glc) for 4 h (E-H). All data were normalized to the DMSO and 
are shown as mean ± SEM (N/n = 4/12). *p < 0.05, **p < 0.01, ***p <0.001 vs the controls 
accordingly. Different letters above bars (H) indicate p < 0.05 between groups. 
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Figure 5: Mechanism of the effect of IVAS on 2-[14C(U)]-deoxy-D-glucose uptake.  
Myotubes, differentiated for 96 h in 5.5 mM glucose and 10 nM insulin (Normal) or in 25 
mM glucose and 50 nM insulin (High Glc/Ins), were starved of glucose, insulin and serum in 
the presence of various concentrations of IVAS for 4 h, followed by the same IVAS treatment 
together with 0.15 µCi/ml 2-[14C(U)]-deoxy-D-glucose (0.55 mM; 2-DG) for 30 min. Panel 
A shows the absolute 2-DG uptake, whereas panel B shows the same data but normalized to 
basal level for each condition, to enable visualization of the relative effect of IVAS. Panel C 
shows the same treatment but with 30 µM IVAS or 30 µM isovanillic acid (IVA) ± 100 nM 
insulin in the 30 min incubation. The effects of 5 µM wortmannin (Wort) or 20 µM indinavir 
(Ind) on 2-DG uptake, stimulated by 100 nM insulin (Ins) or 30 µM IVAS (30 min 
incubations), were explored against the DMSO-treated controls (D). Myotubes were also 
treated with IVAS acutely, i.e. bypassing the 4 h pre-treatment, in the presence of Wort or Ind 
during the 30 min incubation with 0.55 mM 2-[1-14C(U)]-deoxy-D-glucose (E). All data are 
shown as mean ± SEM (N/n = 4/12). *p < 0.05, **p < 0.01, ***p < 0.001 vs controls 
accordingly.  
		
- 23 - 
 
Figure 6: IVAS upregulates GLUTs and PI3K, and activates Akt.  
Myotubes were differentiated in 5.5 mM glucose and 10 nM insulin (Normal) or 25 mM 
glucose and 50 nM insulin (High Glc/Ins) and then treated with 30 µM IVAS or DMSO for 4 
h while starved of glucose, insulin and serum. Troponin T protein (A), GLUT4 protein (B) 
GLUT1 protein (C) and PI3K p85α protein (D) were measured using automated capillary 
Western blotting relative to α-actinin or α-actinin 1, or to troponin T and α-actinin 
accordingly. The response to the antibodies was optimized in the linear dose-response range 
(Fig. S1-S4). After the 4 h starvation/incubation with IVAS or DMSO, myotubes were 
incubated with 0.55 mM glucose and 30 µM IVAS, 100 nM insulin (Ins, positive control), 
IVAS and insulin combined, insulin and 5 µM wortmannin (Wort, negative control), or 
DMSO controls for 15 min. Total lysates were analyzed in the same way, with Akt or 
phospho-Akt (Ser473) (P-Akt) and α-actinin antibodies (optimized as shown in Fig. S5) (E). 
All data shown are mean ratios of the target protein/loading control ± SEM (N = 3). Different 
letters above bars denote where p < 0.05 between treatments.  
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Figure 7: Proposed mechanisms of action by which IVAS increases glucose uptake and 
metabolism in human skeletal muscle.  
Numbered green arrows show sites of action of IVAS: 1) PI3K (p85α) is upregulated; 2) Akt 
phosphorylation is acutely increased; 3) total GLUT4 is upregulated; 4) GLUT4-mediated 
glucose uptake is increased. Plasma membrane proteins: blue – GLUT4 (also shown stored in 
cytosolic vesicle); light green – insulin receptor. Ins – insulin; P – phosphate; hexagons 
represent glucose.  
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Discussion 
 
Human immortalized LHCN-M2 myoblast differentiation to myotubes was accompanied by 
increased troponin T expression (33) while α-actinin protein, which increases with Z-line 
formation but not before, was unchanged (40), both as expected. The myotubes were 
responsive to insulin, a characteristic of skeletal muscle (41). GLUT4 increased with 
differentiation while GLUT1 decreased, consistent with previous data (42). Differentiation in 
high glucose and high insulin increased DCF-fluorescence, a marker of intracellular ROS 
levels in the LHCN-M2 myotubes, although the overall rate of differentiation was unchanged. 
The two conditions, a normal or high glucose and insulin environment, were chosen for many 
of the experiments here, to compare effects amplified in a higher oxidative stress 
environment.  
 
The gut microbiome produces a large number of small molecules from its supply of nutrients 
and other components which reach it via the small intestine. One characteristic is that there 
are multiple catabolites from a single food source or even from a pure compound (43, 44). 
After consumption of coffee, for example, the gut microbiome metabolites predominantly 
include DHFA, DHFA-sulfate and FA-sulfate (44), and these are derived from chlorogenic 
acids. Whole grains, including cereal brans, give comparable profiles derived from covalently 
bound phenolic acids (45, 46). We therefore tested mixtures of some of these metabolites, 
including conjugates, characteristically derived from either the small intestine or from the 
colonic microbiota (Fig. 2). Using a non-metabolizable derivative of glucose, 2-DG, we 
found that some combinations of metabolites such as ferulic acid derivatives showed an 
insulin-like effect in cells differentiated in high glucose and high insulin conditions, but not 
in normal glucose/insulin; while others, such as the resveratrol conjugates and the phenolic 
acid sulfates mixture, produced a robust effect under both normal and high Glc/Ins. Using 
labelled glucose as a marker allows the metabolism of glucose to be assessed, leading to end 
products such as CO2 or lactate, which are expelled into the medium, or glycogen, which is 
stored intracellularly. Some of the metabolite mixtures lowered the amount of 14C-label 
intracellularly, which, together with the enhanced uptake of glucose evident from the 2-DG 
data, indicates a stimulation of glucose metabolism leading to enhanced secretion of the 14C-
label (47). 
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For the ferulic acid mixture, only the sulfated conjugates, FA4S and DHFA-4S, were 
responsible for the stimulation of glucose transport and the latter alone for the increased 
metabolism. DHFA-4S, the most active component, is derived almost entirely following the 
action of the gut microbiota on a range of substrates to produce DHFA, which, after 
absorption in the colon, is then sulfated by sulfotransferases in the liver. Unconjugated ferulic 
acid has been shown to increase (deoxy)glucose uptake in primary porcine and human 
myotubes (48, 49) as well as into muscle L6 myotubes while upregulating GLUT4 and PI3K 
(50). However, unconjugated ferulic acid is not a microbial metabolite and does not exist in 
plasma in the free form in significant concentrations (44). These data show that the 
production of DHFA-4S from the gut microbiome could affect glucose uptake and 
metabolism in muscle, but that the effect would be mostly evident at chronic high glucose 
concentrations, which exist in metabolic syndrome with impaired glucose tolerance or in 
diabetes. 
 
The mixture of flavonol conjugates, or individual compounds, exerted only minimal effects 
on muscle cell uptake of glucose or 2-DG. These conjugates are products of small intestine 
and hepatic metabolism, and are not derived from the gut microbiota (18, 20). At very high 
concentrations, flavonol aglycones were claimed to increase 2-DG uptake in L6 myotubes 
(51) and quercetin increased glucose uptake via AMPK activation independently of insulin in 
C2C12 and L6 muscle cells (52, 53), but these aglycones are not present at sufficient 
concentration in plasma to exert a significant effect (54).  
 
Resveratrol is a highly bioactive molecule that is absorbed in the small intestine and its 
presence in blood does not depend on action of the gut microbiota (18). The resveratrol 
conjugates increased basal 2-DG uptake and glucose metabolism in both normal and high 
Glc/Ins myotubes, restoring the lowered 2-DG transport and negating the longer term effect 
of insulin in the latter. The increased transport was attributable to R4G and R3S, but only 
R4G was shown to increase metabolism. Resveratrol aglycone has been shown previously to 
increase (deoxy)glucose uptake in muscle, possibly involving AMPK. Elevated uptake by 
resveratrol in rodent myotubes was dependent on GLUT4 translocation through activation by 
sirtuins and AMPK and involving PI3K/Akt pathway activation (55, 56).  
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The phenolic sulfates are almost entirely derived from the action of the gut microbiota (29), 
with subsequent hepatic sulfation. They increased basal 2-DG uptake in normal and high 
Glc/Ins myotubes and even potentiated the effect of insulin in the latter. Of the compounds 
tested here, this group displayed the most prominent activity, however, the mixture did not 
have an effect of glucose metabolism. The increased transport was solely due to IVAS, which 
also increased basal metabolism in normal and high Glc/Ins when tested as a single 
metabolite. There are very few reports on the biological activity of IVAS. It has been 
identified as a plasma metabolite following consumption of berries or cyanidin 3-O-glucoside 
(29, 57) and as a phase II conjugate of protocatechuic acid (PCA) (58), but in those studies 
was (analytically) undistinguishable from VAS. PCA dose-dependently increased 
(deoxy)glucose uptake in primary human muscle cells (49), and mimics insulin by activating 
the insulin receptor to increase glucose uptake in human adipocytes (59). PCA and its 
metabolite(s) may have an effect on both pathways that stimulate GLUT4 translocation on L6 
myotubes (60).  
 
In our study, IVAS-stimulated 2-DG uptake was dose-dependent and, as for insulin, exhibited 
a greater effect in the high Glc/Ins myotubes. Inhibition of IVAS-stimulated uptake by 
wortmannin and indinavir indicated that the mechanism was dependent on PI3K signaling 
and GLUT4 translocation (Fig. 7). IVAS also upregulated GLUT4 and PI3K p85α, as well as 
activating Akt in the short term. IVAS is relatively hydrophilic with a LogP of -0.73, and so 
would not enter the myotubes without facilitated transport, while IVA is more hydrophobic 
(LogP of 1.81) and could enter cells by passive diffusion (61). We therefore suggest that the 
most likely action of IVAS and IVA is on the insulin receptor on the surface of the LHCN-
M2 cell, since these cells do not express the OATs (see supplementary table S1) which are 
necessary for uptake of molecules such as IVAS (62). 
 
The data presented here has shown that conjugated catabolites, derived from the action of gut 
microbiota, affect glucose uptake and metabolism in human skeletal LHCN-M2 myotubes. 
Compounds such as DHFA-4S and IVAS were particularly potent, and formation of these 
compounds absolutely require action of the gut microbiota; DHFA and derivatives are almost 
absent in ileostomist subjects who have had their colon surgically removed (63). Studies on 
foods from which IVAS is known to be ultimately formed by the gut microbiota have shown 
some beneficial effects in vivo. Supplementation with blueberry bioactive compounds for 6 
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weeks improved insulin sensitivity in obese, insulin-resistant participants (64) and, when 
bread was consumed with berries, less insulin was needed to control the post-prandial glucose 
(65).  
 
Interactions between colonic microbiota and host tissues mediated by metabolites such as 
SCFA have been studied previously, in particular for butyrate (13), which has the ability to 
act on many tissues including muscle (7, 14). The work presented here identifies novel effects 
of alternative gut microbiome-derived molecules on muscle cells which could have 
implications on the interaction with skeletal muscle tissue in vivo. Although some activity 
was observed on phenolic metabolites produced during absorption by the small intestine, the 
most active molecules were derived from metabolism involving the gut microbiota. 
Importantly, these molecules have been detected in blood in humans, and their pathways of 
post-prandial metabolism have been well described (29, 44). We have focused here on the 
effects on glucose uptake and metabolism, as accurate and timely regulation of these 
processes is vital for correct functioning of muscle cells. With the skeletal muscle accounting 
for up to 75% of postprandial glucose disposal (4), improving insulin-stimulated glucose 
uptake in muscle cells through nutritional regulation of the gut microbiome could lead to 
improved systemic glucose metabolism and enhanced muscle performance with concurrent 
beneficial effects for the host. 
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Supplementary Material 
 
 
Figure S1: Antibody validation for Western analysis of troponin T and α-actinin 1. 
Different total protein concentrations of differentiated LHCN-M2 whole cell lysates were 
analyzed for troponin T and α-actinin 1 and both antibodies were run in the same capillary on 
the automated western blotting system “WES” (ProteinSimple) to test for linearity of signals. 
Electropherogram view (A) and gel-blot (lane) view (B). The peak areas were used to 
establish a standard curve for each antibody when duplexed (C).  
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Figure S2: Antibody validation for Western analysis of GLUT4 and α-actinin 1. 
Different total protein concentrations of differentiated LHCN-M2 whole cell lysates were 
analyzed for GLUT4 and α-actinin 1 and both antibodies were run in the same capillary on 
the automated western blotting system “WES” (ProteinSimple) to test for linearity of signals. 
Electropherogram view (A) and gel-blot (lane) view (B). The peak areas were used to 
establish a standard curve for each antibody when duplexed (C). The specificity of the peak at 
~47 kDa was supported by running the LHCN-M2 lysate alongside a human skeletal muscle 
whole cell lysate (HuSkM WCL) as a positive control and HepG2, Caco-2/TC7 and HUVEC 
total cell lysate negative controls (D).  
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Figure S3: Antibody validation for Western analysis of GLUT1 and α-actinin protein. 
Different total protein concentrations of differentiated LHCN-M2 whole cell lysates were 
analyzed for GLUT1 and α-actinin and both antibodies were run in the same capillary on the 
automated western blotting system “WES” (ProteinSimple) to test for linearity of signals. 
Electropherogram view (A) and gel-blot (lane) view (B). The peak areas were used to 
establish a standard curve for each antibody when duplexed (C).  
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Figure S4: Antibody validation for Western analysis of regulatory unit p85α of PI3K 
and troponin T protein. 
Differentiated LHCN-M2 whole cell lysates were analyzed with PI3K p85α and troponin T 
antibodies at different concentrations run in the same capillary on the automated western 
blotting system “WES” (ProteinSimple) to test for linearity of signals. Electropherogram 
view (A) and gel-blot (lane) view (B). The peak areas were used to establish a standard curve 
for each antibody when duplexed (C). Note, troponin T was chosen as a loading control for 
PI3K p85α because the MW of the latter is too close to that of α-actinin (1). 
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Figure S5: Antibody validation for Western analysis of Akt and p-Akt with α-actinin. 
Differentiated LHCN-M2 whole cell lysates were analyzed for total and phospho-Akt (P-
Akt). Antibodies for Akt or P-Akt were run in the same capillary with α-actinin on the 
automated western blotting system “WES” (ProteinSimple) to test for linearity of signals. 
Electropherogram view (A, B) and gel-blot (lane) view (C). The peak areas were used to 
establish a standard curve for each antibody when duplexed (C). Note, the α-actinin curve 
consists of mean data of each of the curves run with Akt and P-Akt (D).  
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Table S1: Relevant changes in mRNA of LHCN-M2 cells during differentiation*. 
Gene # Protein 
FPKM 1 
Ratio to 
Actinin 
Differentiation 
fold-change 
Day 0 Day 4 Day 0 Day 4 FPKM Ratio 
181856 GLUT4 0.05 7.29 0.0003 0.11 146 323 
117394 GLUT1 126 58.8 0.83 0.86 0.46 1.03 
118194 Troponin T2 (cardiac) 74.5 1103 0.49 16.1 14.8 32.8 
72110 α-Actinin 1 152 68.8 1.00 1.00 0.45 1.00 
145675 PI3K α 7.85 9.93 0.05 0.14 1.26 2.80 
105221 Akt2 45.1 33.3 0.30 0.48 0.74 1.63 
169047 IRS1 13.7 11.8 0.09 0.17 0.86 1.91 
171105 INSR 3.54 5.64 0.02 0.08 1.59 3.53 
104812 GYS1 38.29 130.6 0.25 1.90 3.41 7.56 
197901 OAT1 (SLC22A6) 0 0 - - - - 
137204 OAT2 (SLC22A7) 0 0 - - - - 
149452 OAT3 (SLC22A8) 0 0 - - - - 
168065 OAT4 (SLC22A11) 0 0 - - - - 
* Using total RNA-seq gene quantification data in files ENCFF581EE and ENCFF580JSN 
(LHCN-M2 myoblasts (Day 0) and myotubes (Day 4) respectively) taken from the ENCODE 
database (66). 
1 Fragments Per Kilobase of transcript per Million mapped reads.  
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